Toronto, ON; December 13, 2024 – Proteocyte AI—an innovative company that develops and commercializes individualized tests to predict risk of developing cancer, and StrataDx—a clinical and anatomic pathology diagnostic laboratory, announce a new strategic partnership agreement for the U.S. market.
Mark Hammar, CEO of Proteocyte AI states, “We are excited to have fully executed our Lab Service Agreement (LSA) with StrataDX, our second U.S. based lab partner. We expect StrataDX to come online in Q1 2025 following validation and regulatory filings. Not only will this partnership give us access to StrataDx’s expertise and successful track record in providing a full array of laboratory services, it also provides us with additional capacity to process our Straticyte test, an advanced prognostic lab test predicting risk of oral cancer.”
– 30 –
About StrataDX
StrataDx is a national diagnostic laboratory located in Lexington, Massachusetts dedicated to providing best-in-class pathology services to save lives. Led by dermatopathology experts, StrataDx provides advanced diagnostics for a wide range of skin conditions including melanocytic and soft tissue lesions, dermatoses, and lymphomas. Board-certified oral pathologists represent decades of expertise across a wide range of clinical specialties. StrataDx is considered a leader in testing for the dermatology market. For more information, visit stratadx.com.
About Proteocyte
Proteocyte is a personalized medical diagnostics company located at the MaRS Centre, in Toronto, Ontario. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.
For more information please contact:
Todd Conrad
Sales & Marketing Advisor
416-779-4806
[email protected]